2242758-08-1
Chemical Structure
Tesnatilimab
Synonym(s): JNJ-64304500; IPH-2301; NN-8555
- CAS No.: 2242758-08-1
- Formula:N/A
- Molecular Weight:(143.9 kDa)
IUPAC Name: 4-amino-1,1,1-trifluoro-2-(trifluoromethyl)butan-2-ol
SMILES: [Tesnatilimab]
Biological Activity: Tesnatilimab (JNJ-64304500) is a human IgG4 monoclonal antibody targeting NKG2D, with a KD value of 9.2 pM[1][2]. Tesnatilimab blocks the binding of ligands to the NKG2D receptor, thereby inhibiting downstream proinflammatory cytokine, cytotoxic mediator signaling pathways and proinflammatory immune responses. Tesnatilimab is applicable to research related to Crohn's disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tesnatilimab | 99.80% | Tesnatilimab (JNJ-64304500) is a human IgG4 monoclonal antibody targeting NKG2D, with a KD value of 9.2 pM. Tesnatilimab blocks the binding of ligands to the NKG2D receptor, thereby inhibiting downstream proinflammatory cytokine, cytotoxic mediator signaling pathways and proinflammatory immune responses. Tesnatilimab is applicable to research related to Crohn's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Zhou J, et al. Model-Based Investigation of Inadequate Efficacy of Tesnatilimab, an Anti-Natural Killer Group 2 Member D Monoclonal Antibody, in Moderately to Severely Active Crohn Disease. J Clin Pharmacol. 2023;63(8):928-942. [Content Brief]
- [2]. Allez M, et al. A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn's Disease. J Crohns Colitis. 2023;17(8):1235-1251. [Content Brief]
Keywords
